Before You Calculate AI Training ROI, Check These Three Things

Most AI business cases in the pharma industry are built on licence cost and projected hours saved. The numbers are clean, and the sources are easy to defend, but the components that actually drive return sit somewhere less visible.

Our CSO Jason Hill and Consultant Trainee Anna Kakkonen have been researching what actually drives the return on AI training investment in pharma, building a financial model to pressure-test where the real cost and return come from. Under realistic adoption assumptions, the AI training programme for 50 members pays for itself in about eight months and returns 292% over two years. Three things stood out from the research.

Three things that move the numbers

The costs that never make it into the business case. Regulatory review, output validation, and the compliance overhead of bringing a new tool into a GxP environment. The internal time spent supporting people, documenting the tool, and reworking the processes around it. None of this is hidden on purpose. It simply gets discovered mid-rollout instead of during planning. Leave it out of the financial model, and the case looks stronger on paper than it will in practice.

The J-curve. Return on an AI investment does not move in a straight line. It dips first, even for the first five to six months. The organisation pays the full cost while people are still mid-learning curve, and performance in the first months can look worse than before the rollout. The dip is normal, because it takes time for people to learn and step out of manual routines to adapt to new ways of working. What matters is which direction the curve turns afterwards.

Change management. The direction of the curve is decided here, not in the tool selection. Whether someone owns the rollout after the training period ends, whether teams get support long enough to move past the learning stage, whether using the new way of working is expected or useful. This is what turns the curve up rather than flat and creates returns.

The technology alone doesn't create the return

The pattern behind all three is the same. Technology that is adopted because it is expected, because competitors have it, or because the organisation wants to be able to say it has it, produces licence fees and not much else. Technology that is adopted to solve something specific in an existing process, on the other hand, produces a return, because there is a process to compare against and a reason to keep using it.

The tool sets a ceiling on what is possible. How it is implemented decides how close anyone gets to that ceiling.

No single metric, but a wide enough set

The last thing the financial model made obvious is that there is no single way to calculate ROI across all cases. The boundaries of what metrics to include within the calculations have to be drawn case by case: which costs count, which benefits count, over which time horizon, for which team. But case by case is not the same as narrow. The set of metrics has to be wide enough to hold the visible factors but also the beneath-the-surface, meaningful ones: the hidden costs, a time horizon long enough to see the dip and the recovery, and the quality of the change management around it.